Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2023 20:45 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies Feedback obtained from U.S. Food and Drug Administration (FDA) ...
June 20, 2023 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Study Results Relating to LX9211 and INPEFA™ (Sotagliflozin) at the American Diabetes Association’s 83rd Scientific Sessions

LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE WOODLANDS, Texas, June 20, 2023 (GLOBE...
June 15, 2023 17:00 ET | Source: Lexicon Pharmaceuticals, Inc.

UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of...
June 06, 2023 16:01 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference

THE WOODLANDS, Texas, June 06, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies 2023 Global Healthcare Conference, taking...
June 05, 2023 16:01 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares

THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent...
June 01, 2023 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering...
May 31, 2023 16:01 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces Proposed Public Offering of Common Stock

THE WOODLANDS, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and...
May 26, 2023 16:05 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence...
May 10, 2023 16:30 ET | Source: Lexicon Pharmaceuticals, Inc.

New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure

Sotagliflozin reduced the risk of cardiovascular death and heart failure readmissions in patients hospitalized for worsening heart failure events in SOLOIST-WHF study Sotagliflozin NDA for treatment...
May 02, 2023 16:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,...